Decoy Therapeutics
DCOY
1 hedge funds and large institutions have $3.33M invested in Decoy Therapeutics in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
67% less funds holding
Funds holding: 3 → 1 (-2)
87% less capital invested
Capital invested by funds: $25M → $3.33M (-$21.7M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.43M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.26M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$1.86M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$1.07M |
| 5 |
Millennium Management
New York
|
-$301K |
DCOY Hedge Fund Activity: Q2 2018 in Review
1 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2018, worth a combined $3.33M — down 87% from $25M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of DCOY and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Ameriprise, exiting entirely with an estimated $3.43M sold.
- 1 institutional investor held Decoy Therapeutics (DCOY) as of Q2 2018, down from 3 in Q1 2018.
- Funds reported $3.33M of Decoy Therapeutics stock for Q2 2018, down 87% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q2 2018 and 2 closed out, a net change of -2 holders.
- The largest Decoy Therapeutics seller in Q2 2018 was Ameriprise, an estimated $3.43M sold.
Based on aggregated 13F filings for Q2 2018.